🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Important study in NEJM ❤️ seeing Mazen Noureddin, MD, MHSc front page! 😁for treatments to reverse #cirrhosis ⚠️careful not to over interpret negative phase 2b with *signals* 🧐everyone should learn about FGF21, a fascinating hormone at the intersection of liver metabolism and fibrogenesis

Original Article: Efruxifermin in Compensated Liver Cirrhosis Caused by MASH (SYMMETRY trial) nej.md/4kru98f EASLnews | #EASLCongress

What delivered yesterday’s India-Pak ‘ceasefire’? After 15 days on the ground in Kashmir, here are the unemotional facts—devoid of predictable international ownership battles & narrative management. ndtv.com/india-news/ind…

"Truth is that the Circumstances of 1971 are not the Circumstances of 2025. There are differences" - SHASHI THAROOR talking sense

MASLD pathway for PCPs. sciencedirect.com/science/articl…

Address to the nation. x.com/i/broadcasts/1…

Tirzepatide was superior to semaglutide with respect to weight loss and waist circumference at week 72. nejm.org/doi/full/10.10…

Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) nej.md/44ZeMPz EASO | #ECO2025

Tirzepatide leads to greater weight loss and waist reduction than semaglutide at max doses. In a 72-week study, tirzepatide users lost up to 21% of body weight vs ~10% with semaglutide. More tirzepatide users hit ≥10%, 15%, 20%, and 25% weight loss targets. Waist circumference

Should we wait for response to medical therapy for BCS in the era of endovascular interventions? Find out from our RCT in the best of EASL slide deck! EASLnews The Baveno Cooperation: an EASL Consortium Shalimar AIIMS, New Delhi 🇮🇳 Valdig Group AASLD INASL

Expert opinion on what is the real world approach to management of BCS? Akash Roy Anand V Kulkarni Dr Nipun Verma Yujun_Wong Hanna Blaney, MD, MPH Juan G Abraldes Steven Bollipo Saher Sabri Jahnvi Dhar Sunil Taneja Dr Ashish Kumar Santhosh E Kumar

Simple and rational management #algorithm for #MASLD in Asian #Indians with type 2 #diabetes (Such management in #diabetes published globally for first time). For pdf, email: [email protected]

Prescribing therapies for MASH but unsure of treatment response? The MASH Resolution Index, or FAST score may be helpful 🔥off the press HEPATOLOGY Journal Rohit Loomba AASLD journals.lww.com/hep/abstract/9…

In this international, collaborative effort led by Douglas Chee, we estimate the presence of health policies directed at reducing the burden of HCC CGH American Gastroenterological Association (AGA) Jörn Schattenberg Cheng Han Ng Arndt Vogel Yong Loo Lin School of Medicine Rashid Lui 雷諾信 Jimmy Che-To Lai cghjournal.org/article/S1542-…

Thank you DBT/WT India Alliance for highlighting our work!! I truly couldn’t have set up the lab without the funding from IA- Department of Biotechnology Wellcome!! Thank you IIT Kanpur Mehta Family Center for Engineering in Medicine BSBE@IITK for the support!!

The association between LDL reduction and coronary heart disease (CHD) risk reduction is sizable and confirmed by - Prospective cohort studies - Mendelian randomization - RCTs There really is no room to deny it. You can't get clearer than this:

New study shows that the ketogenic diet significantly increases the risk of heart attack and stroke. Social media influencers in shambles.

#WATCH | Delhi | "...The Indus Waters Treaty is held in abeyance and will continue to be held in abeyance until the cross-border terrorism by Pakistan is credibly and irrevocably stopped... The only thing which remains to be discussed on Kashmir is the vacating of illegally

📢 It’s OVER. The “lean MASLD paradox”? Just bad measurement. ❎MASLD with overweight BMI weren’t healthier! We were using the wrong metric. ↗️Waist circumference-related indices show a dose-dependent mortality risk across 3 prospective cohorts. Let’s reframe how we assess

Heartiest congratulations to Prof Ajay Duseja on receiving the EASL Distinguished International Recognition Award 2025! A proud moment for Indian 🇮🇳 Hepatology and a well-deserved honour for a lifetime of contributions to liver disease research and care. 👏 #EASL2025 EASLnews